FMO5 and diabetic retinopathy: The observed results are consistent with the investigation of Al-Shabrawey et al. [64], who demonstrated that simvastatin could protect against the early signs of diabetic retinopathy by preventing NADPH oxidase-mediated activation of Stat3.